Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2/PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-31

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, the usual standard of palliative treatment used in patients with diagnosed oligometastatic cancer in accordance with the local clinical recommendations is chemotherapy and/or a symptomatic course of radiation therapy in doses less than ablative ones The aim of the study is to increase the effectiveness of treatment of patients with tumors of various localizations with oligometastases in the bones and internal organs with the help of stereotactic radiation therapy.

The method of stereotactic radiation therapy will be applied in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy treatment T1-4, N0-3, M0-1, over 18 years of age at the start of treatment, compared with standard methods of palliative therapy in those same patient models.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SBRT for Extra-cranial Oligorecurrent Tumor

NCT02410187

Recurrent Cancer

UNKNOWN PHASE2

OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites

NCT06856603

Metastatic Disease

RECRUITING PHASE2

Radiotherapy for Extracranial Oligometastatic Breast Cancer

NCT04646564

Breast Cancer Metastatic

RECRUITING PHASE3

Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer

NCT03461822

Radiotherapy

UNKNOWN

Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases

NCT02759783

Prostate Cancer Breast Cancer Carcinoma, Non-Small-Cell Lung

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1\. A patient with a previously verified diagnosis of a malignant neoplasm of one of the localizations (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64) who meets the inclusion criteria, after randomization by random numbers into the study group, is carried out:

1. 3-dimensional/4-dimensional computed tomography for simulation using specialized fixation devices (the choice of the method of computed tomography and fixing devices will be carried out depending on the location of the metastasis).
2. The resulting images are added to the contouring program.
3. Delineation of targets and risk organs is performed.
4. The clinical volumes and margins for the errors are determined.
5. Prescribing the total dose per target and dose limits for critical structures.
6. Dosimetric planning of the course of external-beam radiation therapy is carried out.
7. Irradiation sessions are carried out on a linear accelerator with a multi-leaf collimator, with the presence of a function for visual control of the target using cone tomography with a kilo-voltage/mega-voltage beam.
8. When the target is localized in the lungs, liver, and adrenal glands, in order to reduce the radiation load on the surrounding healthy tissues and achieve the necessary control over the position of metastasis, irradiation is carried out with a deep breath hold, or at certain phases of respiration.

Tumor localization / Description /Total focal dose, Gy/ Number of fractions /Single focal dose, Gy/ Irradiation mode:

Lung Tumors:

1. of 3cm or less located in the parenchyma TD45Gy in 3Fx with 15Gy every day
2. adjacent to the chest wall or less than 3 cm TD50Gy in 5Fx with 10Gy every day
3. within 2 cm of the mediastinum or brachial plexus TD60Gy in 8Fx with 7.5Gy every day

Bones TD24Gy in 3Fx with 8Gy every day

Brain Metastasis

1. volume from 0.5 to 5 cm3 TD20-22Gy in 1Fx at a time
2. volume of metastasis is from 5 to 10 cm3 TD16-18Gy or TD18-20Gy in 1 Fx at a time

Liver Radiation regimen selection based on tolerance of surrounding tissues and diligence to critical structures TD30-60Gy in 3-8Fx with 6-15Gy every day

Adrenal Glands TD60Gy in 8Fx with 7.5Gy every day

2\. The expected duration of the patient's participation in clinical testing, a description of the sequence and duration of all periods of clinical testing, including the period of follow-up, if any;

Periods of clinical testing:

* pre-hospital (includes a comprehensive examination of the patient before treatment)
* inpatient (includes pre-radiation training for up to 3 working days, remote radiation therapy, from one to eight working days);
* follow-up - after 3, 6, 9, 12, 18, 24 months;
* collection and processing of the received data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oligometastatic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stereotactic Ablative Radiotherapy (SABR) arm

The method of stereotactic radiation therapy in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy T1-4, N0-3, M0-1, aged over 18 years at the time of initiation of treatment

Group Type EXPERIMENTAL

stereotactic ablative radiation therapy

Intervention Type RADIATION

stereotactic ablative radiation therapy in effective doses to each metastatic site

Standart care arm

Palliative radiation therapy or chemotherapy alone in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy T1-4, N0-3, M0-1, aged over 18 years at the time of initiation of treatment

Group Type ACTIVE_COMPARATOR

palliative radiation therapy

Intervention Type RADIATION

palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)

Chemotherapy

Intervention Type DRUG

prescribed drug line

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stereotactic ablative radiation therapy

stereotactic ablative radiation therapy in effective doses to each metastatic site

Intervention Type RADIATION

palliative radiation therapy

palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)

Intervention Type RADIATION

Chemotherapy

prescribed drug line

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically confirmed malignant formation (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64).
2. 0-2 points on the WHO/ECOG scale of assessment of the general condition of the patient.
3. The absence of disease progression after the current line of chemotherapeutic treatment.
4. The number of oligometastases is not more than 3 in one organ, in the presence of a multi-organ lesion.
5. The total number of distant metastases is no more than 5.
6. Life expectancy of more than 6 months for brain metastases (GPA-score)
7. The possibility of SBRT for all distant metastases, in accordance with the criteria specified in the study design.
8. Making decisions on the inclusion of a patient in the study protocol based on the results of an interdisciplinary consultation consisting of an oncologist, a chemotherapist and a radiotherapist.
9. Signed informed consent

Exclusion Criteria

1. 3-4 points on the WHO/ECOG scale of assessment of the general condition of the patient
2. The complete response of all foci to the chemotherapy.
3. Distant metastases only in the brain, without damage to bones and other organs.
4. Brain metastasis of more than 3 cm in one dimension, requiring surgical treatment.
5. Distant metastasis in the brain stem and spinal cord.
6. The size of at least one distant metastasis is more than 5 cm.
7. Previously performed radiation therapy on one of the metastatic foci.
8. Metastatic lesion of the pleura, membranes of the brain or peritoneum.
9. The impossibility of CTT for all distant metastases, in accordance with the criteria specified in the study design.
10. Invasion into great vessels (aorta, carotid arteries, pulmonary arteries, etc.), organs of the digestive tract (esophagus, stomach, intestines), skin.
11. Compression of the spinal cord by distant metastasis according to instrumental studies.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No